ZITHROMAX (azithromycin dihydrate) by Pfizer is drug. Approved for infection. First approved in 1995.
Drug data last refreshed 1w ago · AI intelligence enriched 2w ago
ZITHROMAX (azithromycin dihydrate) is an oral macrolide antibiotic approved in 1995 for the treatment of bacterial infections. It works by inhibiting bacterial protein synthesis, making it effective against a broad spectrum of gram-positive and gram-negative organisms. The suspension formulation enables flexible dosing across adult and pediatric populations.
LOE-stage product with moderate competitive pressure (30%) signals transition planning; brand teams are likely consolidating resources and managing decline rather than scaling.
drug. [see ]
PASS Study To Evaluate The Potential Of Zithromax To Cause Ocular Problems In Pediatric Patients
Zithromax-SR 2g, Special Investigation (Regulatory Post Marketing Commitment Plan)
Zithromax EV in Community-Acquired Pneumonia (CAP)
A Pediatric Taste Test Study of Omnicef Versus Zithromax Antibiotic Suspension Medications
Worked on ZITHROMAX at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moZITHROMAX offers limited career growth opportunity given its LOE-approaching lifecycle and mature market status. Roles on this product are typically focused on defending market share, managing generics, and optimizing manufacturing and logistics rather than launching innovation or scaling commercial reach.